Clinical trial
Randomized Phase I/II of RAD001 in Advanced Hepatocellular Carcinoma (HCC)
NCT00390195 · National Health Research Institutes, Taiwan, Other · Unknown status
Key facts
| NCT number | NCT00390195 |
|---|---|
| Title | Randomized Phase I/II of RAD001 in Advanced Hepatocellular Carcinoma (HCC) |
| Official title | Randomized Phase I/II of Rapamycin Analog, RAD001, in Advanced Hepatocellular Carcinoma - With a Pharmacokinetic Study of RAD001 |
| Lead sponsor | National Health Research Institutes, Taiwan, Other |
| Collaborators | Novartis Industry |
| Status | Unknown status |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Hepatocellular Carcinoma |
| Intervention type | Drug |
| Interventions | RAD001 (everolimus) |
| Enrollment | 134 |
| Start date | Oct 1, 2006 |
| Primary completion | Jun 1, 2010 |
| Completion | Jun 1, 2011 |
| First posted | Oct 19, 2006 |
| Last update posted | Jul 2, 2009 |
| Countries | Taiwan |
At a glance
- 1–9 Study sites
- No Results posted
- 1–9 FDA inspections linked to this trial
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: